Craniopharyngioma clinical trials at UCSF
1 research study open to eligible people
Craniopharyngioma is a rare type of brain tumor. UCSF is studying the use of two drugs, Nivolumab and DAY101, in treating this condition in children and young adults. The focus of this study is to see how well these drugs work together and how safe they are.
Showing trials for
Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
open to eligible people ages 1-39
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
San Francisco, California and other locations
Our lead scientists for Craniopharyngioma research studies include Sabine Mueller, MD, PhD, MAS.
Last updated: